Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with fanconi anemia

África González-Murillo, M. Luz Lozano, Lara Álvarez, Ariana Jacome, Elena Almarza, Susana Navarro, José C. Segovia, Helmut Hanenberg, Guillermo Guenechea, Juan A. Bueren, Paula Río

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Fanconi anemia (FA) is an inherited genetic disease characterized mainly by bone marrow failure and cancer predisposition. Although gene therapy may constitute a good therapeutic option for many patients with FA, none of the clinical trials so far developed has improved the clinical status of these patients. We have proposed strategies for the genetic correction of bone marrow grafts from patients with FA, using lentiviral vectors (LVs). Here we investigate the relevance of the expression of FANCA to confer a therapeutic effect in cells from patients with FA-A, the most frequent complementation group in FA. Our data show that relatively weak promoters such as the vav or phosphoglycerate kinase (PGK) promoter confer, per copy of FANCA, physiological levels of FANCA mRNA in lymphoblastoid cell lines, whereas the cytomegalovirus and, more significantly, spleen focus-forming virus (SFFV) promoters mediated the expression of supraphysiological levels of FANCA mRNA. Insertion of the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) or a mutated WPRE into the 3′ region of PGK-FANCA LVs significantly increased FANCA mRNA levels. At the protein level, however, all tested vectors conferred, per copy of FANCA, similar and physiological levels of the protein, except SFFV LVs, which again conferred supraphysiological levels of FANCA. In spite of their different activity, all tested vectors mediated a similar phenotypic correction in FA-A lymphoblastoid cell lines and also in hematopoietic progenitors from patients with FA-A. On the basis of the efficacy and safety properties of PGK LVs, a PGK LV carrying FANCA and a mutant WPRE is proposed as an optimized vector for the gene therapy of patients with FA-A.

Original languageEnglish
Pages (from-to)623-630
Number of pages8
JournalHuman Gene Therapy
Volume21
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Fanconi Anemia
Genetic Therapy
Phosphoglycerate Kinase
Woodchuck Hepatitis B Virus
Spleen Focus-Forming Viruses
Messenger RNA
Bone Marrow
Cell Line
Bone Neoplasms
Inborn Genetic Diseases
Therapeutic Uses
Cytomegalovirus
Proteins
Clinical Trials
Transplants
Safety

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

González-Murillo, Á., Lozano, M. L., Álvarez, L., Jacome, A., Almarza, E., Navarro, S., ... Río, P. (2010). Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with fanconi anemia. Human Gene Therapy, 21(5), 623-630. https://doi.org/10.1089/hum.2009.141

Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with fanconi anemia. / González-Murillo, África; Lozano, M. Luz; Álvarez, Lara; Jacome, Ariana; Almarza, Elena; Navarro, Susana; Segovia, José C.; Hanenberg, Helmut; Guenechea, Guillermo; Bueren, Juan A.; Río, Paula.

In: Human Gene Therapy, Vol. 21, No. 5, 01.05.2010, p. 623-630.

Research output: Contribution to journalArticle

González-Murillo, Á, Lozano, ML, Álvarez, L, Jacome, A, Almarza, E, Navarro, S, Segovia, JC, Hanenberg, H, Guenechea, G, Bueren, JA & Río, P 2010, 'Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with fanconi anemia', Human Gene Therapy, vol. 21, no. 5, pp. 623-630. https://doi.org/10.1089/hum.2009.141
González-Murillo, África ; Lozano, M. Luz ; Álvarez, Lara ; Jacome, Ariana ; Almarza, Elena ; Navarro, Susana ; Segovia, José C. ; Hanenberg, Helmut ; Guenechea, Guillermo ; Bueren, Juan A. ; Río, Paula. / Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with fanconi anemia. In: Human Gene Therapy. 2010 ; Vol. 21, No. 5. pp. 623-630.
@article{7e37ce2ef1804b7686d7a1b1a5949924,
title = "Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with fanconi anemia",
abstract = "Fanconi anemia (FA) is an inherited genetic disease characterized mainly by bone marrow failure and cancer predisposition. Although gene therapy may constitute a good therapeutic option for many patients with FA, none of the clinical trials so far developed has improved the clinical status of these patients. We have proposed strategies for the genetic correction of bone marrow grafts from patients with FA, using lentiviral vectors (LVs). Here we investigate the relevance of the expression of FANCA to confer a therapeutic effect in cells from patients with FA-A, the most frequent complementation group in FA. Our data show that relatively weak promoters such as the vav or phosphoglycerate kinase (PGK) promoter confer, per copy of FANCA, physiological levels of FANCA mRNA in lymphoblastoid cell lines, whereas the cytomegalovirus and, more significantly, spleen focus-forming virus (SFFV) promoters mediated the expression of supraphysiological levels of FANCA mRNA. Insertion of the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) or a mutated WPRE into the 3′ region of PGK-FANCA LVs significantly increased FANCA mRNA levels. At the protein level, however, all tested vectors conferred, per copy of FANCA, similar and physiological levels of the protein, except SFFV LVs, which again conferred supraphysiological levels of FANCA. In spite of their different activity, all tested vectors mediated a similar phenotypic correction in FA-A lymphoblastoid cell lines and also in hematopoietic progenitors from patients with FA-A. On the basis of the efficacy and safety properties of PGK LVs, a PGK LV carrying FANCA and a mutant WPRE is proposed as an optimized vector for the gene therapy of patients with FA-A.",
author = "{\'A}frica Gonz{\'a}lez-Murillo and Lozano, {M. Luz} and Lara {\'A}lvarez and Ariana Jacome and Elena Almarza and Susana Navarro and Segovia, {Jos{\'e} C.} and Helmut Hanenberg and Guillermo Guenechea and Bueren, {Juan A.} and Paula R{\'i}o",
year = "2010",
month = "5",
day = "1",
doi = "10.1089/hum.2009.141",
language = "English",
volume = "21",
pages = "623--630",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with fanconi anemia

AU - González-Murillo, África

AU - Lozano, M. Luz

AU - Álvarez, Lara

AU - Jacome, Ariana

AU - Almarza, Elena

AU - Navarro, Susana

AU - Segovia, José C.

AU - Hanenberg, Helmut

AU - Guenechea, Guillermo

AU - Bueren, Juan A.

AU - Río, Paula

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Fanconi anemia (FA) is an inherited genetic disease characterized mainly by bone marrow failure and cancer predisposition. Although gene therapy may constitute a good therapeutic option for many patients with FA, none of the clinical trials so far developed has improved the clinical status of these patients. We have proposed strategies for the genetic correction of bone marrow grafts from patients with FA, using lentiviral vectors (LVs). Here we investigate the relevance of the expression of FANCA to confer a therapeutic effect in cells from patients with FA-A, the most frequent complementation group in FA. Our data show that relatively weak promoters such as the vav or phosphoglycerate kinase (PGK) promoter confer, per copy of FANCA, physiological levels of FANCA mRNA in lymphoblastoid cell lines, whereas the cytomegalovirus and, more significantly, spleen focus-forming virus (SFFV) promoters mediated the expression of supraphysiological levels of FANCA mRNA. Insertion of the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) or a mutated WPRE into the 3′ region of PGK-FANCA LVs significantly increased FANCA mRNA levels. At the protein level, however, all tested vectors conferred, per copy of FANCA, similar and physiological levels of the protein, except SFFV LVs, which again conferred supraphysiological levels of FANCA. In spite of their different activity, all tested vectors mediated a similar phenotypic correction in FA-A lymphoblastoid cell lines and also in hematopoietic progenitors from patients with FA-A. On the basis of the efficacy and safety properties of PGK LVs, a PGK LV carrying FANCA and a mutant WPRE is proposed as an optimized vector for the gene therapy of patients with FA-A.

AB - Fanconi anemia (FA) is an inherited genetic disease characterized mainly by bone marrow failure and cancer predisposition. Although gene therapy may constitute a good therapeutic option for many patients with FA, none of the clinical trials so far developed has improved the clinical status of these patients. We have proposed strategies for the genetic correction of bone marrow grafts from patients with FA, using lentiviral vectors (LVs). Here we investigate the relevance of the expression of FANCA to confer a therapeutic effect in cells from patients with FA-A, the most frequent complementation group in FA. Our data show that relatively weak promoters such as the vav or phosphoglycerate kinase (PGK) promoter confer, per copy of FANCA, physiological levels of FANCA mRNA in lymphoblastoid cell lines, whereas the cytomegalovirus and, more significantly, spleen focus-forming virus (SFFV) promoters mediated the expression of supraphysiological levels of FANCA mRNA. Insertion of the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) or a mutated WPRE into the 3′ region of PGK-FANCA LVs significantly increased FANCA mRNA levels. At the protein level, however, all tested vectors conferred, per copy of FANCA, similar and physiological levels of the protein, except SFFV LVs, which again conferred supraphysiological levels of FANCA. In spite of their different activity, all tested vectors mediated a similar phenotypic correction in FA-A lymphoblastoid cell lines and also in hematopoietic progenitors from patients with FA-A. On the basis of the efficacy and safety properties of PGK LVs, a PGK LV carrying FANCA and a mutant WPRE is proposed as an optimized vector for the gene therapy of patients with FA-A.

UR - http://www.scopus.com/inward/record.url?scp=77951961355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951961355&partnerID=8YFLogxK

U2 - 10.1089/hum.2009.141

DO - 10.1089/hum.2009.141

M3 - Article

VL - 21

SP - 623

EP - 630

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 5

ER -